A recent review published in the World Journal of Pediatric Surgery consolidates current understanding of long-term liver injury in patients who have undergone Kasai portoenterostomy for biliary atresia (BA). The research identifies key biological mechanisms, including persistent gene signatures, ductular reaction, and elevated serum bile acids, that continue to drive liver fibrosis despite successful initial surgical intervention. The findings aim to refine assessment methods and guide future therapeutic strategies for this chronic liver disorder.
Introduction: Biliary Atresia and Post-Surgical Challenges
Biliary atresia (BA) is a condition characterized by the destruction of bile ducts shortly after birth, leading to cholestasis, inflammation, and rapid liver fibrosis. While Kasai portoenterostomy is a surgical procedure that can restore bile flow and delay the need for liver transplantation, a significant number of patients continue to develop progressive liver fibrosis after the surgery.
Current methods for assessing liver fibrosis, such as liver biopsies, are invasive and can be prone to variability, while existing non-invasive markers often lack sufficient accuracy for early stages of the disease. Researchers note that the biological factors driving fibrosis after successful surgery appear to differ from those present at the onset of BA, indicating a need for a deeper understanding of these long-term mechanisms.
Research Overview
Researchers from the University of Helsinki published a comprehensive review on December 30, 2025, in the World Journal of Pediatric Surgery. The review examined the progression of liver fibrosis following successful Kasai portoenterostomy for BA, evaluated existing fibrosis assessment methods, and connected molecular and histological changes observed in patients to their long-term clinical outcomes. The goal of the review was to clarify why surgery alone often does not prevent chronic liver damage and to identify potential targets for improved long-term monitoring and treatment strategies.
Key Findings on Fibrosis Progression
The review highlighted several key aspects of liver fibrosis progression after Kasai portoenterostomy:
- Variable Trajectories: Post-surgical liver fibrosis courses are highly variable. Over half of patients eventually develop cirrhosis, while a substantial number show stable or regressing fibrosis, particularly when bile flow is effectively and durably restored.
- Persistent Molecular Activity: Molecular profiling indicates that despite a decrease in inflammation post-surgery, gene signatures associated with fibrogenesis and extracellular matrix production persist.
- Role of Ductular Reaction: An abnormal expansion of bile duct-like cells and transdifferentiating hepatocytes, known as ductular reaction, strongly correlates with fibrosis severity and native liver survival. Advanced imaging and AI-assisted histological analyses suggest these ductular cells actively participate in matrix remodeling.
- Bile Acid Dysregulation: Elevated serum bile acids were identified as key predictors of fibrosis progression, portal hypertension, and long-term outcomes. These elevated bile acids may contribute to fibrosis by stimulating ductular reaction and myofibroblast activation.
- Assessment Limitations: Non-invasive fibrosis markers, including elastography and serum biomarkers, are considered useful for detecting advanced disease, but their sensitivity is limited for identifying early stages of fibrosis.
These findings collectively characterize BA as a chronic, evolving liver disorder in which surgery modifies, but does not entirely eliminate, the biological factors contributing to fibrotic injury.
Clinical Implications
The research suggests that understanding fibrosis progression post-surgery requires a focus on long-term tissue-level changes rather than solely on short-term bilirubin normalization. Persistent ductular reaction and bile acid dysregulation are identified as active disease processes, not merely residual damage. Recognizing these mechanisms may provide insight into the varied disease courses observed in patients with similar surgical outcomes.
The authors emphasize that improved risk stratification, informed by molecular and histological markers, is crucial for identifying patients who could benefit most from emerging antifibrotic or bile acid-modulating therapies. Specific clinical implications include:
- Non-Invasive Biomarkers: Development of reliable non-invasive biomarkers could reduce the need for repeated biopsies and enable earlier detection of high-risk patients.
- Targeted Therapies: Targeting bile acid signaling pathways or ductular reaction may offer new therapeutic approaches to slow fibrosis progression and extend native liver survival.
- Long-Term Follow-up: The review underscores the need for long-term, mechanism-based follow-up strategies, suggesting that surgical success should not be considered a definitive endpoint. Such an approach could improve patient outcomes, optimize the timing for transplantation, and guide future clinical trials focused on modifying disease progression.